Combining nuclear pore inhibition, specifically targeting either the structural components of the nuclear pore complex (NPC) or the inhibition of nuclear export via XPO1 (exportin 1), with other established cancer therapies such as chemotherapy or immunotherapy could enhance treatment outcomes. The gene discussed is XPO1; the disease is cancer.